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ABSTRACT 
BACKGROUND: The genetics of depression has been explored in genome-wide association studies 
that focused on either major depressive disorder or depressive symptoms with mostly negative 
ﬁndings. A broad depression phenotype including both phenotypes has not been tested previously 
using a genome-wide association approach. We aimed to identify genetic polymorphisms 
signiﬁcantly associated with a broad phenotype from depressive symptoms to major depressive 
disorder. 
METHODS: We analyzed two prior studies of 70,017 participants of European ancestry from general 
and clinical populations in the discovery stage. We performed a replication meta-analysis of 28,328 
participants. Single nucleotide polymorphism (SNP)-based heritability and genetic correlations were 
calculated using linkage disequi-librium score regression. Discovery and replication analyses were 
performed using a p-value-based meta-analysis. Lifetime major depressive disorder and depressive 
symptom scores were used as the outcome measures. RESULTS: The SNP-based heritability of major 
depressive disorder was 0.21 (SE 5 0.02), the SNP-based heritability of depressive symptoms was 
0.04 (SE 5 0.01), and their genetic correlation was 1.001 (SE 5 0.2). We found one genome-wide 
signiﬁcant locus related to the broad depression phenotype (rs9825823, chromosome 3: 61,082,153, 
p 5 8.2 3 10–9) located in an intron of the FHIT gene. We replicated this SNP in independent samples 
(p 5 .02) and the overall meta-analysis of the discovery and replication cohorts (1.0 3 10–9). 
CONCLUSIONS: This large study identiﬁed a new locus for depression. Our results support a 
continuum between depressive symptoms and major depressive disorder. A phenotypically more 
inclusive approach may help to achieve the large sample sizes needed to detect susceptibility loci for 
depression. 
The etiology of depression—a worldwide leading cause of disability (1)—is not well understood. As 
indicated by family, twin, and adoption studies, genetic factors mediate part of vulnerability to 
major depressive disorder (MDD) with a modest heritability of around 40% (2). However, we 
understand little of the speciﬁc genetic architecture of MDD. Multiple genome-wide association 
studies (GWASs) for MDD have been published (3–10). The largest MDD GWAS was the mega-
analysis by the MDD Working Group of the Psychiatric Genomics Consortium (PGC). In that study, 
more than 9000 MDD cases and 9500 control subjects were analyzed, but no association with MDD 
reached genome-wide signiﬁcance (7). Recently, the CONVERGE (China, Oxford, and VCU 
Experimental Research on Genetic Epidemiology) consortium identiﬁed two genome-wide signiﬁcant 
associations in 5303 Chinese women with severe and recurrent MDD (near the SIRT1 gene, p 5 2.53 
3 10–10, and in an intron of the LHPP gene, p 5 6.45 3 10–12)(11). A GWAS of depressive symptoms 
(23%–29% heritability)(12,13) in the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium in approximately 50,000 people from the general population found no 
genome-wide signiﬁcant associations (14). Owing to the relatively small sample sizes, the previous 
GWASs of depressive disorders and depressive symptoms were arguably underpowered to detect 
small genetic effects (15,16). 
Depression can be conceptualized along a continuum of severity from subthreshold or minor 
depression to MDD of varying severity (e.g., mild, moderate, severe) (17). Using a continuum 
approach may augment statistical power because sample size can be increased substantially and 
patients who fall into the gray area can be assessed. Several lines of evidence support a depression 
continuum. In longitudinal studies, there is an increased risk of MDD in patients with minor 
depression and subthreshold depression (18,19). Statistical studies of disorder classiﬁcation 
(taxometric) suggested that severity of depression is continuously di-tributed and that there is no 
discontinuity in the latent structure of depression (19,20). Family studies report that relatives of 
probands with milder forms of depression have greater risk of MDD compared with relatives of 
probands without any mood disorders (21–24). A higher number of depressive symptoms is related 
to greater disability, worse quality of life, and higher mortality risk (18,25–29). MDD and continuous 
measures of depression are highly correlated, and severity of depressive symptoms along the 
continuum is linear (30,31). 
The goal of the current study was to combine the results of the largest GWAS using categorical 
lifetime MDD and continuous measures of depression to identify genetic variants underlying the 
entire depression continuum. 
METHODS AND MATERIALS 
Study Design and Samples 
This study was a collaboration between investigators on the PGC MDD and CHARGE genome-wide 
association meta-analyses (GWAMA). In the discovery phase, we aggregated two GWAMAs 
published in 2013 (7,14). Basic descriptive features and phenotype deﬁnitions of the contributing 
samples are provided in Supplemental Table S1. The mega-analysis of MDD consisted of nine studies 
of 9240 cases meeting international criteria for lifetime MDD and 9519 healthy control subjects. The 
CHARGE meta-analysis of depressive symptoms included 22 cohorts and comprised 51,258 persons. 
Each cohort contributing to the GWAMA of the PGC and CHARGE was distinct. In the replication 
analyses, 16 case-control studies with DSM-IV MDD (6718 cases and 13,453 control subjects) were 
included along with 8157 subjects from the general population with assessment of depressive symp-
toms. All subjects were of European ancestry. Institutional review boards approved all studies, and 
all participants provided written informed consent. 
Phenotype Characteristics 
In the PGC GWAMA, MDD was established with structured clinical interviews (e.g., Clinical Interview 
Schedule–Revised, Diagnostic Interview for Genetic Studies, and Structured Clinical Interview for 
DSM-IV). All clinical evaluations were made by experienced clinicians or interviewers. Most cases 
were ascertained from clinical sources. Control subjects were screened in most of the studies to 
require the absence of MDD and were recruited from the general population. Full details about the 
PGC samples can be found in the previous publication (7). In the CHARGE GWAMA, depressive symp-
toms were assessed with validated questionnaires. Measures include the Center for Epidemiological 
Studies–Depression scale, Geriatric Depression Scale, Patient Health Question-naire-9, and Beck 
Depression Inventory-II, mostly assessing depressive symptoms during previous weeks rather than 
lifetime MDD (14). Persons with schizophrenia, bipolar disorder, or dementia were excluded. 
Persons aged 40 years or older with genotype data and depressive symptom scores were included. 
The 16 MDD case-control replication samples were part of an expanded but unpublished PGC MDD 
analysis. MDD was diagnosed with interviews. In the depressive symptom replication cohort, the 
Health and Retirement Study, the 8-item Center for Epidemiological Studies–Depression scale was 
applied. Respondents were excluded if they were under 40 years of age or displayed evidence of 
cognitive impairment. 
Genotyping and Imputation 
In the PGC samples (Supplemental Table S1), individual genotypes were assembled, processed 
through a central quality control pipeline, and imputed using the CEU (Central Europe) and TSI 
(Toscani in Italy) HapMap3 reference panels. Quality control procedures were extensive (7). In the 
CHARGE cohorts, genotype quality control and imputation were con-ducted in each study 
separately. The imputation reference was the HapMap2 CEU panel (14). In the MDD replication 
cohorts (Supplemental Table S3), imputation was performed using IMPUTE2 or SHAPEIT (chunk size 
of 3 Mb and default parameters). The imputation reference set consisted of 2186 phased haplotypes 
from the 1000 Genomes Project. In the Health and Retirement Study, imputation was performed 
using the HapMap2 CEU reference panel. 
Statistical Analyses 
Linkage disequilibrium score regression was used to compute the single nucleotide polymorphism 
(SNP)-based heritability and the genetic correlation using the 1000 Genomes CEU reference panel 
(32). 
In the PGC GWAMA, a logistic regression analysis was used to test the association between MDD and 
imputed SNP dosages under an additive model and adjusting for study indicators and ﬁve principal 
components (7). In the CHARGE GWAMA, a linear regression analysis was applied to test the 
association of depressive symptom score on imputed SNP dosages in the contributing studies 
adjusting for age and sex. Analyses were adjusted for principal components for most, but not all, 
cohorts in the CHARGE GWAMA. A p-value-based meta-analysis was applied in the CHARGE GWAMA 
(14). Effect size estimates were based on a dichotomous outcome in the PGC and on a continuous 
outcome in the CHARGE GWAMA. To combine these effect estimates, a p-value-based meta-analysis 
weighted by sample size with METAL (http://www.sph.umich.edu/csg/abecasis/metal/) was used. 
This method allows different weights for each study and takes into account the direction of effect at 
each SNP (33). To specify the direction of the effect, the PGC used the logistic regression coefﬁcient 
beta and the CHARGE used z scores. Weights were based on the number of MDD cases in the PGC 
study (n 5 9240), and the number of individuals in the CHARGE with clinically signiﬁcant depressive 
symptoms (n 5 5976) using population-speciﬁc cutoff scores of the questionnaires was considered 
for weighting. To test whether the results are affected by different sample size weightings, equal 
weights per study, or no weight as suggested by Stouffer et al. (34), we carried out a series of 
sensitivity analyses. 
We selected the genome-wide signiﬁcant SNPs in two loci from the discovery stage for replication. 
After analyzing these data, we performed a p-value-based meta-analysis combining all replication 
samples. Furthermore, we analyzed the results of the discovery and all replication samples weighting 
for number of cases. 
RESULTS 
In the discovery stage, we performed a GWAMA in 70,017 participants of European ancestry by 
combining the PGC MDD (7) and CHARGE GWAMA (14). We applied a linkage disequilibrium score 
regression to the summary statistics from each study to compute the SNP-based heritabilities and 
the genetic correlation. As reported previously (35), the SNP-based liability scale heritability of MDD 
was 0.2 (SE 5 0.02) for 20% of prevalence. The lambda was 1.1 and the regression intercept was 1.0 
(SE 5 0.01). The SNP-based heritability of depressive symptoms was 0.04 (SE 5 0.01). The lambda was 
1.1 and the regression intercept was 1.0 (SE 5 0.01). The SNP-based heritability of the broad 
depression phenotype was 0.3 (SE 5 0.04). MDD and depressive symptoms showed signiﬁcant 
coheritability (1.001, SE 5 0.2, z score 5 4.6, p 5 4.6 3 10–6). This result supports the contention of a 
continuum between depressive symptoms and MDD. However, the genetic correlation should be 
interpreted carefully because linkage disequilibrium regression is quite sensitive to environ-mental 
confounding and, like twin studies, often lacks precision. In addition, different evaluation methods of 
the depression phenotypes might cause different genetic correlation estimates that cannot easily be 
compared. 
We conducted a meta-analysis of the PGC MDD and the CHARGE depressive symptoms GWAMA 
using a weighted, p-value-based meta-analysis. The results are summarized in Figure 1 and 
Supplemental Figures S1 to S3. The combined meta-analysis was conducted for 918,921 SNPs. Two 
loci were genome-wide signiﬁcant: an SNP in an intron of the FHIT gene (rs9825823, chromosome 3: 
61,082,153, p 5 8.2 3 10–9) and an SNP in an intron of PLEK2 (rs9323497, chr14: 67,873,128, p 5 3.3 
3 10–8)(Table 1). All SNPs with a p value of association, 5 3 10–5 are presented in Supplemental 
Table S2. Using different weights or Stouffer’s unweighted method had only slight effects on the 
results (data not shown). Supplemental Figures S4 and S5 show forest plots for two SNPs shown in 
Table 1. 
Table 2 presents the replication analyses and the meta-analysis of discovery and replication results. 
One of the genome-wide signiﬁcant variants within the FHIT gene (rs9825823) was associated with 
the depression continuum in the replication cohorts (z score 5 2.4, p 5 .02). The result of the ﬁnal 
meta-analysis of discovery and replication samples also indicated a positive replication as indexed by 
a lower p value (z score 5 6.1, p 5 1.0 3 10–9). This SNP had a positive association with depressive 
symptoms in the CHARGE study (p 5 5.5 3 10–4), and a similar pattern was observed in the PGC 
study (p 5 4.1 3 10–6). The SNP in an intron of PLEK2 (rs9323497) was not related to the depression 
continuum signiﬁcantly (z score 5 0.2, p 5 .90). 
We performed an additional replication analysis of our two genome-wide signiﬁcant SNPs using the 
publicly available data of the recently published GWAMA of depressive disorders in a sample of 
Chinese women (the CONVERGE study) (11). In CONVERGE, rs9825823 (odds ratio 5 1.01, p 5 .12) 
and rs9323497 (odds ratio 5 0.97, p 5 .0002, with a different direction of association than in our 
discovery sample) were not related to depression at the genome-wide signiﬁcance level, although 
the latter reached nominal signiﬁcance. However, in the joint meta-analysis of the Health and 
Retirement Study, the PGC MDD study, and CONVERGE study, we found that the association 
between rs9825823 and the depression continuum (z score 5 2.85, p 5 .004) was slightly stronger 
than our initial replication analysis. When these replication and discovery samples were combined, 
the association with our top hit also became stronger (analysis without the CONVERGE data: z score 
5 6.1, p 5 1 3 10–9; analysis with the CONVERGE data: z score 5 6.2, p 5 6.8 3 10–10). Results of 
additional replication analyses are given in Supplemental Table S4. 
 
 
DISCUSSION 
We report the results of a combined GWAMA of the depression continuum including MDD (18,759 
cases and control subjects) and depressive symptoms (51,258 participants). In the discovery stage, 
we found genome-wide signiﬁcant associations in the FHIT and PLEK2 genes. One SNP in the intron 
of the FHIT gene showed a signiﬁcant association in the combined analysis of discovery and 
replication samples of MDD and depressive symptoms samples, and it exceeded a genome-wide 
signiﬁcance threshold. 
The signiﬁcant locus (rs9825823, chr3: 61,082,153) maps to the intronic region of the FHIT gene, a 
tumor suppressor protein implicated in several cancers (36). FHIT is expressed in multiple brain 
regions (amygdala, anterior cingulate cortex, caudate nucleus, prefrontal cortex, hippocampus, and 
hypothalamus; http://www.gtexportal.org/home/gene/FHIT). It plays an important role in oxidative 
stress and level of DNA damage (37), biological processes implicated in MDD (38,39). 
FHIT is a circadian clock modiﬁer gene (40) and has been related to daytime sleepiness (41), which 
may be salient to the etiology of depression. 
In a GWAS of recurrent, early-onset MDD, three SNPs located in the FHIT gene were among the 
strongest associations in the overall and sex-stratiﬁed analyses (8), although none had genome-wide 
signiﬁcance. Genetic variants located in FHIT have been reported in genetic studies of anxiety (42), 
autism (43), mental stress (44), comorbid depressive syndromes and alcohol dependence (45), 
citalopram-induced side effects (46), and a latent class analysis of MDD symptoms (7), but none has 
met genome-wide signiﬁcance. 
 
Several methodological aspects should be discussed. First, we evaluated the depression continuum 
by combining cases from clinical populations diagnosed with MDD and participants from the general 
population who had been assessed for depressive symptoms. Such an inclusive approach may 
increase heterogeneity of the phenotype especially because lifetime MDD was evaluated, whereas 
depressive symptoms indicate past weeks only. If anything, such an approach would cause an 
underestimation of the effects because less information on depressive symptoms was obtained. 
However, the advantages of a large sample can outweigh the disadvantages of a less precisely 
deﬁned phenotype. This has been observed in the GWAS of educational attainment that was 
successfully used as a proxy for intelligence (47). Our additional replication analysis showed that 
increasing the sample size yielded a stronger association of the top hit with the depression 
continuum. It is complex to calculate statistical power of the current analysis because quantitative 
and qualitative measures were combined. In the current study, a genetic association with the 
depression continuum may reﬂect an effect on broad depressive phenotypes but could also be 
accounted for by an association with low levels of general well-being (12%–18%heritability) that co-
occur with depressive symptoms (48). Second, we used a p-value-based meta-analysis because 
effect estimates could not be directly evaluated in a straight-forward manner. Third, the 
heterogeneity of the imputation methods used in the PGC and CHARGE discovery samples might 
reduce the statistical power. However, different imputation references did not change the results in 
the published PGC MDD study (7). 
In conclusion, in this large GWAMA of a broad depression phenotype, we detected a locus 
associated with depression in clinical and general population samples. Our results suggest the 
importance of a broader depression phenotype to identify genetic variants underlying depression. 
Large samples with different depression phenotypes may also help to disentangle the genetic 
background of different forms of depression. 
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